Ahmed S. Osman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ahmed S. Osman has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed M. Refaat
Zoology Department, Faculty of Science, Minia University, El-Minia, 61519, Egypt.
1 shared publication - Ahmed Mohamed Mahmoud Abdelfattah Elkassas
College of Medicine, Alexandria University, Alexandria 26571, Egypt
1 shared publication - Ahmed Roshdi Hamed Ahmed
Microbial Chemistry Department, National Research Centre, Cairo, Egypt
1 shared publication - Alia Khairy Mahmoud
Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Sohag University, Sohag 82524, Egypt
1 shared publication - Amany Mohamed Hamed
Chemistry Department, Faculty of Science, Sohag University, Sohag 82524, Egypt
1 shared publication - Azza M. A. Abouelella
Department of Clinical Pharmacology, Faculty of Medicine, Sohag University, Sohag 82524, Egypt
1 shared publication
Latest Publications
- Open Access
- 1 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (9) , 4072
Chitosan-Based Taurine Nanoparticles Alleviate Dexamethasone-Induced Pulmonary–Thyroid Axis Dysfunction via Redox–Inflammatory Signaling Modulation in Rats
Dexamethasone induces systemic toxicity, including oxidative stress, inflammation, hematological disturbances, and organ damage, particularly in the lungs and thyroid. Taurine exhibits antioxidant and anti-inflammatory properties, but poor bioavailability limits its efficacy. Nanoparticle delivery may enhance stability and tissue targeting. This study aimed to evaluate the protective effects of taurine-loaded chitosan nanoparticles (Tau–CS NPs) against dexamethasone-induced tissue injury in rats. Forty-eight male Wistar rats were allocated into control, DEXA, DEXA + silymarin, DEXA + taurine, and DEXA + Tau–CS NPs groups. Tau–CS NPs were characterized by TEM, UV–vis, FTIR, encapsulation efficiency, and drug loading. Hematology, oxidative stress markers (CAT, SOD, GSH, MDA), thyroid hormones (T3, T4, TSH, calcitonin), protein profile, lung and thyroid histopathology, and MPO expression were assessed. Tau–CS NPs showed uniform spherical morphology (11–60 nm), high encapsulation (98.2%), and substantial loading (50.36%). Dexamethasone caused hematological, oxidative, thyroidal, and histological disturbances. Tau–CS NPs markedly restored hematological indices, antioxidant defenses, thyroid function, protein profile, and tissue architecture, outperforming free taurine and silymarin. MPO expression was significantly reduced, indicating decreased inflammation. Taurine nanoparticles effectively mitigate dexamethasone-induced systemic and organ-specific toxicity, offering improved bioavailability and targeted delivery, highlighting their therapeutic potential.
- 1 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (9) , 4072
Open AccessChitosan-Based Taurine Nanoparticles Alleviate Dexamethasone-Induced Pulmonary–Thyroid Axis Dysfunction via Redox–Inflammatory Signaling Modulation in Rats
Dexamethasone induces systemic toxicity, including oxidative stress, inflammation, hematological disturbances, and organ damage, particularly in the lungs and thyroid. Taurine exhibits antioxidant and anti-inflammatory properties, but poor bioavailability limits its efficacy. Nanoparticle delivery may enhance stability and tissue targeting. This study aimed to evaluate the protective effects of taurine-loaded chitosan nanoparticles (Tau–CS NPs) against dexamethasone-induced tissue injury in rats. Forty-eight male Wistar rats were allocated into control, DEXA, DEXA + silymarin, DEXA + taurine, and DEXA + Tau–CS NPs groups. Tau–CS NPs were characterized by TEM, UV–vis, FTIR, encapsulation efficiency, and drug loading. Hematology, oxidative stress markers (CAT, SOD, GSH, MDA), thyroid hormones (T3, T4, TSH, calcitonin), protein profile, lung and thyroid histopathology, and MPO expression were assessed. Tau–CS NPs showed uniform spherical morphology (11–60 nm), high encapsulation (98.2%), and substantial loading (50.36%). Dexamethasone caused hematological, oxidative, thyroidal, and histological disturbances. Tau–CS NPs markedly restored hematological indices, antioxidant defenses, thyroid function, protein profile, and tissue architecture, outperforming free taurine and silymarin. MPO expression was significantly reduced, indicating decreased inflammation. Taurine nanoparticles effectively mitigate dexamethasone-induced systemic and organ-specific toxicity, offering improved bioavailability and targeted delivery, highlighting their therapeutic potential.